Eisai

Eisai Establishes Pharma Sales Subsidiary in Vietnam

Thursday, September 17, 2020 - 1:59am

TOKYO, Sept 17, 2020 - (JCN Newswire) - Eisai Co., Ltd. announced today that it has established a new pharmaceutical sales subsidiary in Ho Chi Minh City, the Socialist Republic of Viet Nam (Vietnam), which will be named Eisai Vietnam Co., Ltd. (Eisai Vietnam).

Key Points: 
  • TOKYO, Sept 17, 2020 - (JCN Newswire) - Eisai Co., Ltd. announced today that it has established a new pharmaceutical sales subsidiary in Ho Chi Minh City, the Socialist Republic of Viet Nam (Vietnam), which will be named Eisai Vietnam Co., Ltd. (Eisai Vietnam).
  • Eisai Vietnam is a wholly-owned subsidiary of Eisai.
  • In 1992, Eisai (Thailand) Marketing Co., Ltd., a pharmaceutical sales subsidiary of Eisai, started business in Vietnam through a local agency.
  • With the establishment of Eisai Vietnam, Eisai aims to enhance its own drug sales system in Vietnam, deliver innovative new drugs to more patients in Vietnam, and contribute to improving the benefits of patients and their families.

Eisai to Present Abstracts on Oncology Products and Pipeline at ESMO Virtual Congress 2020

Friday, September 11, 2020 - 2:41am

TOKYO, Sept 11, 2020 - (JCN Newswire) - Eisai Co., Ltd. announced today that a series of abstracts will be presented at the European Society for Medical Oncology (ESMO) Virtual Congress 2020 from September 19 to 21, 2020.

Key Points: 
  • TOKYO, Sept 11, 2020 - (JCN Newswire) - Eisai Co., Ltd. announced today that a series of abstracts will be presented at the European Society for Medical Oncology (ESMO) Virtual Congress 2020 from September 19 to 21, 2020.
  • Both of these presentations have been selected as Late-Breaking Abstracts.
  • Eisai positions oncology as a key therapeutic area, and is aiming to discover revolutionary new medicines with the potential to cure cancer.
  • There is no guarantee that any investigational compounds or investigational uses of FDA-approved products will successfully complete clinical development or gain FDA approval.

Eisai to Take over Manufacturing and Marketing Approval for Equfina 50mg Tablets (Safinamide Mesilate) in Japan from Meiji Seika Pharma

Monday, September 7, 2020 - 1:02am

In Japan, Meiji conducted clinical studies of Equfina and obtained its manufacturing and marketing approval in September 2019.

Key Points: 
  • In Japan, Meiji conducted clinical studies of Equfina and obtained its manufacturing and marketing approval in September 2019.
  • Based on the license agreement signed between Eisai and Meiji, Eisai will take over by transfer the manufacturing and marketing approval of Equfina from Meiji.
  • Eisai, as the manufacturer and distributor of Equfina in Japan, will continue to provide information on the proper usage of Equfina.
  • Equfina, developed by Meiji in Japan, is a once-daily oral treatment for Parkinson's disease.

Eisai to Launch Sahne Medical Spray and Sahne Medical Cream

Tuesday, August 25, 2020 - 4:55am

TOKYO, Aug 25, 2020 - (JCN Newswire) - Eisai Co., Ltd. announced today that it has launched Sahne Medical Spray and Sahne Medical Cream (both are category-2 OTC drugs, "Sahne Medical") on August 25, 2020 at pharmacies and drugstores throughout Japan, as a new product of the Sahne brand lineup which has been a favored hand care for generations.

Key Points: 
  • TOKYO, Aug 25, 2020 - (JCN Newswire) - Eisai Co., Ltd. announced today that it has launched Sahne Medical Spray and Sahne Medical Cream (both are category-2 OTC drugs, "Sahne Medical") on August 25, 2020 at pharmacies and drugstores throughout Japan, as a new product of the Sahne brand lineup which has been a favored hand care for generations.
  • "Sahne Medical Spray" is the first OTC drug spray-type lotion containing Heparinoid.
  • In addition, the tube-type "Sahne Medical Cream" is recommended for relieving unbearable discomfort of dryness upon going out, as it is convenient to carry.
  • With the new launch of Sahne Medical, a pharmaceutical product, Eisai is now able to provide a remedy for skin problems that it had not been able to contribute to before.

Eisai Pharmaceuticals to Make the ON3 Next-Generation Life-Science and Lifestyle Campus its U.S. Headquarters

Tuesday, August 11, 2020 - 2:05pm

The company plans to transfer up to 1,200 Eisai corporate staff and research & development functions from Woodcliff Lake to Nutley in late 2021.

Key Points: 
  • The company plans to transfer up to 1,200 Eisai corporate staff and research & development functions from Woodcliff Lake to Nutley in late 2021.
  • Prism Capital Partners, owners Eugene Diaz and Edwin Cohen, is the real estate developer for the 116-acre ON3 site.
  • The new, 15-story, ON3 Eisai Inc. location features significant space to offer a workplace-of-the-future for the existing employee population and allow for company expansion.
  • To learn more about Eisai Inc., please visit us at https://us.eisai.com and follow us on Twitter and LinkedIn.

Eisai Alzheimer's Disease Pipeline Research to be Presented at Virtual AAIC 2020, Including BAN2401 and Lemborexant Data and a Biomarker Symposium

Friday, July 24, 2020 - 1:46pm

BAN2401 is an investigational humanized monoclonal antibody for Alzheimer's disease that is the result of a strategic research alliance between Eisai and BioArctic.

Key Points: 
  • BAN2401 is an investigational humanized monoclonal antibody for Alzheimer's disease that is the result of a strategic research alliance between Eisai and BioArctic.
  • As such, BAN2401 may have the potential to have an effect on disease pathology and to slow down the progression of the disease.
  • In March 2014, Eisai and Biogen entered into a joint development and commercialization agreement for BAN2401 and the parties amended that agreement in October 2017.
  • Eisai will book all sales for BAN2401 following marketing approval and launch, and profits will be equally shared between the companies.

Eisai to Present Latest Data on Pipeline Assets in the Area of Alzheimer's Disease and Dementia at the Alzheimer's Association International Conference (AAIC) 2020

Wednesday, July 22, 2020 - 9:04am

Regarding BAN2401, the clinical study design of the newly initiated Phase III clinical study AHEAD 3-45 for preclinical Alzheimer's disease (AD) patients will be presented orally.

Key Points: 
  • Regarding BAN2401, the clinical study design of the newly initiated Phase III clinical study AHEAD 3-45 for preclinical Alzheimer's disease (AD) patients will be presented orally.
  • The safety and efficacy results from a Phase II clinical study on lemborexant (orexin receptor antagonist) targeting Irregular Sleep Wake Rhythm Disorder (ISWRD) associated with AD will be presented.
  • Finally, they will hold a discussion on the future outlook of this classification system for Alzheimer's pharmacological trials and clinical practice.
  • For more information about Eisai Co., Ltd., please visit https://www.eisai.com
    Copyright 2020 JCN Newswire .